VitaLink Research Acquires Comprehensive Clinical Trials to Expand Women's Health Clinical Research Capabilities

On August 13, 2019, VCBeat (WeChat ID: vcbeat) learned that GREENWICH, CT, and GREENVILLE, SC – VitaLink Research (VLR) had announced the acquisition of Comprehensive Clinical Trials (CCT), based in West Palm Beach, Florida. CCT is dedicated to providing Phase II–IV clinical trials, with a focus on women’s health.

The addition of CCT enables VitaLink Research to provide high-quality clinical research to patients in the southeastern United States.

Nick Wright, CEO of VitaLink Research, stated, “Partnering with CCT represents a pivotal step in the company’s expansion into the field of women’s health. The addition of CCT enables us to collaborate with the exceptional team established by Dr. Ackerman. Furthermore, I look forward to working with Dr. Ackerman to strategically enhance our capabilities in clinical research for women’s health, building upon VitaLink’s existing foundation, thereby increasing patient enrollment in these critical studies. Dr. Ackerman, who enjoys global renown in the field of clinical research, will continue to lead CCT’s operations.”

Dr. Ronald Ackerman, Founder of CCT, stated, “I am delighted to collaborate with the VitaLink Research team to further develop our combined business in the coming years. The robust infrastructure established by VitaLink will enable CCT to focus on clinical research and expand our expertise in women’s health across the entire VitaLink network.”

VitaLink Research (VLR) is a network of fully integrated clinical trial sites that connects world-class physicians and medical professionals with site managers and research coordinators, establishes standards for the timely execution of clinical trial protocols, and delivers reliable results across all sites. Founded in 2004, VitaLink Research has 13 offices in the United States, with its headquarters located in Greenville, South Carolina. VLR’s model represents an effective approach to research operations and management, consistently exceeding sponsor and FDA expectations in all quality audits.

Great Point Partners (GPP), founded in 2003 and headquartered in Greenwich, Connecticut, USA, is a healthcare investment firm comprising 28 professionals. It manages approximately $1 billion in equity capital, with investments across the United States, Canada, and Western Europe. GPP is currently making new private equity investments from its $306 million Fund III. The firm manages both private capital (GPP I: $156 million; GPP II: $215 million; GPP III: $306 million) and public equity funds (BioMedical Value Fund: approximately $1.3 billion).

GPP has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing healthcare companies. Its private equity funds invest across the entire healthcare industry, with a particular focus on biopharmaceutical services and supplies, service providers, outsourcing, pharmaceutical infrastructure, and IT support businesses. The firm takes a proactive and proprietary approach to sourcing investments and acquisitions for its portfolio companies.

Comprehensive Clinical Trials (CCT) is one of the most advanced and mature clinical research sites in the United States. CCT is the preferred research organization for many large pharmaceutical companies worldwide. Its goal is to deliver high-quality data reports while ensuring patient compliance and safety. Dr. Ronald Ackerman founded CCT in 2000 with the objective of building a research company from the ground up. The company boasts some of the most experienced researchers in the industry. Currently, CCT serves tens of thousands of patients across numerous therapeutic areas.

(Compiled by Tian Shuhang)